Thread by @AlphSt_India

Torrent Pharmaceuticals Ltd Q4 FY22 Earnings Concall Insights

#TORNTPHARM #TORNTPHARMQ4 #TorrentPharmaceuticals #concall #concalls #insights #results #stocks #TrendingStocks #earnings #stockmarketindia #StockToWatch #finance #stockmarket #Markets
🧵

Q&A Insights: Anubhav A of @CreditSuisse asked about Brazil market, how much the 5 launches the company did in 4Q22 contributed as a percentage of sales. Sanjay Gupta ED said it showed a growth of about 21% and roughly about 13-14% of that is the contribution from new launches.

Q&A Insights: Anubhav A of @CreditSuisse asked how Brazil sales growth is expected in FY23. Sanjay Gupta ED replied that Brazilian GDP growth was about 4-4.5% and next year forecast is less than 1%. So assuming market grows at 8-10%, the company should be well above that.

Q&A Insights: Anubhav A of @CreditSuisse asked if the closedown of the facility in the US would help reduce cost in subsequent quarter. Sudhir Menon CFO said the operating expenses on a full year basis is INR135 crore, which should be the cost saving from the closure for FY23.

Q&A Insights: Damayanti Kerai of @HSBC_IN enquired about Germany market sales going forward. Sanjay ED said it expects sales in 2H23 to be better than 1H23 in terms of growth. The company also has 10-15 launches in FY23, the bulk of which will be coming after Sept. Oct. also.

Q&A Insights: Damayanti Kerai of @HSBC_IN also asked about the tender and retail market ratio in Germany. Sanjay Gupta ED replied that tender sales are roughly 60% of the company’s business in Germany.

Q&A Insights: Damayanti Kerai of @HSBC_IN asked how the company should look at FY23 growth over FY22. Aman Mehta ED said that on a CAGR basis, double digit growth should be doable for the market.

Q&A Insights: Neha M of @BankofAmerica asked that on the field force addition, if all the planned addition is done. Aman ED answered that there would be some additional expansion happening by end of 1Q23. So 4Q22 ended at 3,900 and probably another 200-300 reps by end of 1Q23.

Q&A Insights: Nitin Agarwal of DAM Capital asked about the driver of employee expense reducing QonQ. Sudhir Menon CFO said it was due to reworking of annual incentives, reversal of provisions, plus the reversal of Chairman’s commission.

To read further on the detailed analysis of #TORNTPHARM #Q4 concall Q&A …

alphastreet.com/india/torrent-…